Item 2.02 Results of Operations and Financial Condition.
Please see the disclosure relating to the estimated cash and investments in
marketable securities of Nektar Therapeutics, a Delaware corporation (the
"Company"), set forth under Item 7.01 "Regulation FD Disclosure" of this Current
Report on Form 8-K, which is incorporated by reference into this Item 2.02.
Item 7.01 Regulation FD Disclosure.
On January 6, 2021, the Company announced that President and Chief Executive
Officer, Howard Robin, will make a presentation at the upcoming 39th Annual J.P.
Morgan Virtual Healthcare Conference on Monday, January 11, 2021, at 11:50 a.m.
Pacific Time. The presentation and Q&A session will be accessible via Webcast
through a link posted on the Investor Events Calendar section of the Nektar
website: https://ir.nektar.com/events-and-presentations/events. This Webcast
will be available for replay until February 10, 2021.
In addition, Mr. Robin intends to announce that, based upon the Company's
preliminary estimates, as of December 31, 2020, the Company had cash and
investments of approximately $1.2 billion. This financial information has been
prepared by and is the responsibility of the Company's management and has not
been audited by the Company's independent registered public accounting firm.
Accordingly, the Company's independent registered public accounting firm does
not express an opinion on or provide any other form of assurance with respect to
this preliminary data. This financial information is subject to the completion
of the Company's year-end financial closing procedures, the preparation of the
Company's consolidated financial statements, and the completion of the audit of
the Company's consolidated financial statements as of and for the year ended
December 31, 2020, and the Company's actual results may differ from these
estimates.
The Company expects the presentation and Q&A session will include certain
forward-looking statements regarding the Company's business and proprietary drug
candidates, the timing of the start and conclusion of planned or ongoing
clinical trials, the timing and outcome of regulatory decisions, and future
availability of clinical trial data. Actual results could differ materially from
these forward-looking statements, which are subject to important risks and
uncertainties set forth in the Company's Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission on November 6, 2020. The Company
undertakes no obligation to update forward-looking statements, whether as a
result of new information, future events or otherwise.
The information in this Item 7.01 is being furnished and shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that Section or Sections 11
and 12(a)(2) of the Securities Act of 1933, as amended. The information
contained in this Item 7.01 shall not be incorporated by reference into any
filing with the Securities and Exchange Commission (the "SEC") made by Nektar,
whether made before or after the date hereof, regardless of any general
incorporation language in such filing.
1
© Edgar Online, source Glimpses